BUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌

路透中文

Nov 13, 2025

BUZZ-<a href="https://laohu8.com/S/KRRO">Korro Bio</a> 因试验失败和<a href="https://laohu8.com/S/NVO">诺和诺德</a>交易中止而暴跌

11月12日 - ** 药物开发商Korro Bio KRRO.O股价在延时交易中暴跌76.1%至7.62美元

** KRRO称，其治疗一种罕见肺病和肝病的实验药物KRRO-110在患者体内产生了一种关键蛋白质，但未能达到预期水平。

** 该药物正在对α-1抗胰蛋白酶缺乏症进行测试，这是一种罕见的遗传性疾病，可导致严重的肺部和肝脏疾病。

** 公司还暂停了与诺和诺德NOVOb.CO的许可协议，为期12个月，11月11日生效

** 公司称，合作可能不会产生任何收益，因此 Korro Bio 公司将立即停止相关研发活动

** KRRO 称诺和诺德公司将向 Korro 补偿部分停产成本；此外，Korro 宣布裁员 34

** KRRO 股价今年以来下跌 17.5

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583558193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583558193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583558193?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-13 06:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583558193","market":"us","top_or_hot":-1,"title":"BUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> 因试验失败和<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>交易中止而暴跌</title></head><body><p><span>11月12日</span><span> - </span>** 药物开发商Korro Bio <span>KRRO.O</span>股价在延时交易中暴跌76.1%至7.62美元</p><p>** KRRO称，其治疗一种罕见肺病和肝病的实验药物KRRO-110在患者体内产生了一种关键蛋白质，但未能达到预期水平。</p><p>** 该药物正在对α-1抗胰蛋白酶缺乏症进行测试，这是一种罕见的遗传性疾病，可导致严重的肺部和肝脏疾病。</p><p>** 公司还暂停了与诺和诺德<span>NOVOb.CO</span>的许可协议，为期12个月，11月11日生效</p><p>** 公司称，合作可能不会产生任何收益，因此 Korro Bio 公司将立即停止相关研发活动</p><p>** KRRO 称诺和诺德公司将向 Korro 补偿部分停产成本；此外，Korro 宣布裁员 34</p><p>** KRRO 股价今年以来下跌 17.5 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-13 06:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> 因试验失败和<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>交易中止而暴跌</title></head><body><p><span>11月12日</span><span> - </span>** 药物开发商Korro Bio <span>KRRO.O</span>股价在延时交易中暴跌76.1%至7.62美元</p><p>** KRRO称，其治疗一种罕见肺病和肝病的实验药物KRRO-110在患者体内产生了一种关键蛋白质，但未能达到预期水平。</p><p>** 该药物正在对α-1抗胰蛋白酶缺乏症进行测试，这是一种罕见的遗传性疾病，可导致严重的肺部和肝脏疾病。</p><p>** 公司还暂停了与诺和诺德<span>NOVOb.CO</span>的许可协议，为期12个月，11月11日生效</p><p>** 公司称，合作可能不会产生任何收益，因此 Korro Bio 公司将立即停止相关研发活动</p><p>** KRRO 称诺和诺德公司将向 Korro 补偿部分停产成本；此外，Korro 宣布裁员 34</p><p>** KRRO 股价今年以来下跌 17.5 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4T3WO1PI:1","article_id":"2583558193","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583558193","pubTimestamp":1762988177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌11月12日 - ** 药物开发商Korro Bio KRRO.O股价在延时交易中暴跌76.1%至7.62美元** KRRO称，其治疗一种罕见肺病和肝病的实验药物KRRO-110在患者体内产生了一种关键蛋白质，但未能达到预期水平。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","KRRO":"Korro Bio, Inc."},"translate_title":"BUZZ-Korro Bio plunges on trial failure and Novo Nordisk deal halt","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"BUZZ-Korro Bio 因试验失败和诺和诺德交易中止而暴跌11月12日 - ** 药物开发商Korro Bio KRRO.O股价在延时交易中暴跌76.1%至7.62美元** KRRO称，其治疗一种罕见肺病和肝病的实验药物KRRO-110在患者体内产生了一种关键蛋白质，但未能达到预期水平。** 该药物正在对α-1抗胰蛋白酶缺乏症进行测试，这是一种罕见的遗传性疾病，可导致严重的肺部和肝脏疾病。** 公司还暂停了与诺和诺德NOVOb.CO的许可协议，为期12个月，11月11日生效** 公司称，合作可能不会产生任何收益，因此 Korro Bio 公司将立即停止相关研发活动** KRRO 称诺和诺德公司将向 Korro 补偿部分停产成本；此外，Korro 宣布裁员 34** KRRO 股价今年以来下跌 17.5 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}